The global mycoplasma detection systems market is likely to be valued at US$ 600 Million in FY 2022, up from US$ 560 Million in 2021. During the past year, the industry registered a Y-o-Y increase worth 7.1%. From 2022 to 2032, mycoplasma detection systems sales are poised to flourish at a CAGR of 9.6% to reach a value of US$ 1.5 Billion by the end of 2032.
Demand for mycoplasma detection systems equipment will continue to thrive, with a documented CAGR of 9.6% during the 2015-2021 historical period of assessment, while demand for mycoplasma detection systems in biochemical & pharmaceutical sector proliferated at a rate of 13.3% during the same time period. The APAC will dominate the global market, registering a growth opportunity worth US$ 3.1 Billion from 2022 to 2032.
Fact.MR has predicted the mycoplasma detection systems market to surge at a 9.6% CAGR between 2022 and 2032 in comparison to the 9.3% CAGR throughout the historic period. The increasing emphasis on mycoplasma testing after the occurrence of COVID-19 by the global pharmaceutical companies & research companies boosts the demand for the mycoplasma detection systems kits and reagents across the globe.
Manufacturers are making hefty investments to develop the easy-to-use kits equipment and reduce the cost of systems & services for the detection of bacteria which are complex to detect from microscope.
Want A Detailed Understanding of Market Functioning? Request for a Sample Here –https://www.factmr.com/connectus/sample?flag=S&rep_id=446
Key Challenges to Mycoplasma Detection Systems Industry Expansion
Fact.MR’s recently published analysis report summarizes that the unavailability of trained/skilled molecular biologists is likely to impede the market growth over the projection period. Mycoplasma testing needs certain specialized skills perceived in professional from life sciences, pharmaceutical, electronics, and software industries. The deficiency of trained personnel proficient of conducting molecular biology experiments and interpreting the results is a foremost limitation of testing and containment of COVID-19 in emerging nations.
Moreover, high cost of instruments and long and laborious detection procedure are likely to restrict the mycoplasma testing in clinical market development in the conjecture period.
How Opportunistic are Growth Prospects across North America?
In terms of market contribution, North America captures a dominant share of nearly 32% in the mycoplasma testing market and is likely to maintain its stronghold in the upcoming years.
Based on Fact.MR’s projections, this region is anticipated to expand its market share in the future, owing to its engrained healthcare industry and the mounting occurrence of chronic diseases in the region.
Several factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region.
Which Product Type is Most Preferred in the Mycoplasma detection systems Market?
Mycoplasma detection systems is gaining significant traction in the biopharmaceuticals industry. Biopharmaceuticals represent around one-fourth share of total pharmaceutical industry revenue generation which is growing year on year by a substantial rate.
The superior efficacy of biopharmaceuticals in treating chronic diseases is making them the choice of treatment which in turn is increasing biopharmaceutical production. Mycoplasma is the most common contaminant in the biopharmaceuticals industry; therefore, mycoplasma detection systems devices are gaining significant adoption to ensure biopharmaceuticals product safety. With constantly evolving contamination detection techniques and the growing adoption of biopharmaceuticals in healthcare, this is expected to create several opportunities for mycoplasma detection systems market growth.
Speak To Research Analyst For Detailed Insights: https://www.factmr.com/connectus/sample?flag=AE&rep_id=446
Competitive Landscape
Prominent Mycoplasma detection systems providers are reliant on partnerships, collaborations, acquisitions, and new software launches so as to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.
- In June 2021, Agilent Technologies Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions.
- In Nov 2021, Merck KGaA, a leading science and technology company, announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry to help solve the toughest problems in life science.
Key Segments Covered in the Mycoplasma Detection Systems Industry Survey
Mycoplasma detection systems by Product Type
- Mycoplasma detection systems Kits and Reagents
- Nucleic Acid Detection Kits
- PCR Assays
- Elimination Kits & Reagents
- Others
- Mycoplasma Detection Services
- Mycoplasma Detection Systems
- PCR Based Systems
- Luminescence Based Systems
Mycoplasma Detection Systems by Technique
- PCR Mycoplasma detection systems
- ELISA Mycoplasma detection systems
- Direct & Indirect Assay Mycoplasma detection systems
- Others
Mycoplasma Detection Systems by End User
- Mycoplasma Detection Systems in Pharmaceutical & Biopharmaceutical Companies
- Mycoplasma detection systems in Research Laboratories
- Mycoplasma detection systems in Contract Research Organizations (CROs)
- Mycoplasma detection systems in Academic Research Institutes
Mycoplasma Detection Systems by Region
- North America Mycoplasma Detection Systems Market
- Latin America Mycoplasma Detection Systems Market
- Europe Mycoplasma Detection Systems Market
- Asia Pacific Mycoplasma Detection Systems Market
- Middle East & Africa Mycoplasma Detection Systems Market
Interested to Procure The Data? Inquire here at –https://www.factmr.com/checkout/446
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: [email protected]
Visit Our Website: https://www.factmr.com